Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China

Fineline Cube May 14, 2025

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...

Company

Legend Biotech’s Q1 2025 Results Highlight Carvykti Sales Growth

Fineline Cube May 14, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue...

Company Deals

Sanyou Biopharmaceuticals and TransReco Biotechnology Partner to Advance Novel Drug Formulations

Fineline Cube May 14, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and TransReco (Wenzhou) Biotechnology Co., Ltd. announced a strategic...

Company Deals

Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China

Fineline Cube May 14, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...

Company Drug

BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial

Fineline Cube May 14, 2025

Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...

Company Deals

InnoCare Pharma Partners with Westlake University for Innovative Drug Research

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced a strategic partnership agreement with Westlake...

Company Drug

Betta Pharmaceuticals Secures Macau Approval for Ensartinib

Fineline Cube May 13, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...

Company Deals

OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots

Fineline Cube May 13, 2025

Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...

Company Deals

Genentech to Invest Over $700 Million in North Carolina Drug Manufacturing Facility

Fineline Cube May 13, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest...

Company Drug

Huadong Medicine Presents DR10624 Study Results for Obesity and Hypertriglyceridemia at EASL 2025

Fineline Cube May 13, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its...

Company

Teva Announces 8% Workforce Reduction to Achieve $700 Million Cost-Saving Goal

Fineline Cube May 13, 2025

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has disclosed plans to reduce its workforce by...

Company Deals Drug

Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007

Fineline Cube May 13, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...

Company Deals

Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases

Fineline Cube May 13, 2025

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...

Company Deals

Tenacia Partners with TSH Biopharm for Ztalmy Commercialization in Taiwan

Fineline Cube May 13, 2025

Tenacia Biotechnology, a central nervous system (CNS) specialist backed by Bain Capital, has entered into...

Company Drug

BeiGene’s Sonrotoclax Gains NMPA Priority Review for MCL Treatment

Fineline Cube May 13, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Medical Device

United Imaging Healthcare Gains FDA Approval for uAngio AVIVA Interventional X-ray System

Fineline Cube May 13, 2025

China-based United Imaging Healthcare (UIH, SHA: 688271) announced that it has received marketing approval from...

Policy / Regulatory

Trump Executive Order Seeks to Align US Prescription Drug Prices with Global Standards

Fineline Cube May 13, 2025

U.S. President Donald J. Trump has signed an executive order aimed at aligning prescription drug...

Company Drug

Fosun Pharma’s FCN-159 Granted Breakthrough Therapy Designation for Pediatric LCH

Fineline Cube May 13, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its novel small-molecule...

Company Drug

Merck Sharp & Dohme Launches Recarbrio in China for Bacterial Pneumonia and Infections

Fineline Cube May 13, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official...

Company Deals

Roche Invests $550 Million in Indianapolis Diagnostics Facility for CGM Systems

Fineline Cube May 13, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced plans to invest up to USD 550...

Posts pagination

1 … 216 217 218 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.